Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results from ...

Detalimogene coraplasmid shows a promising CR rate for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with 63% achieving CR at any time. The treatment is well tolerated, with 42% ...

Xilio reports a 27% response rate in MSS CRC patients, showing promising biomarker decreases and favorable safety profile with vilastobart. Initial data show only a 27% preliminary response rate in a ...

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated ...